|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 45/06 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61K 31/385 | (2006.01) | ||
| A61K 31/506 | (2006.01) | ||
| A61K 31/337 | (2006.01) | ||
| C07K 16/28 | (2006.01) | ||
| A61K 33/24 | (2006.01) | ||
| A61K 39/00 | (2006.01) |
| (11) | Number of the document | 2769737 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14162613.5 |
| Date of filing the European patent application | 2009-10-29 | |
| (97) | Date of publication of the European application | 2014-08-27 |
| (45) | Date of publication and mention of the grant of the patent | 2017-04-05 |
| (46) | Date of publication of the claims translation | 2017-06-26 |
| (30) | Number | Date | Country code |
| 226910 P | 2009-07-20 | US | |
| 462168 | 2009-07-30 | US | |
| PCT/US2009/0522 | 2009-07-30 | WO |
| (72) |
Lee, Francis, Y., US
Jure-Kunkel, Maria, US
|
| (73) |
Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Anti-CTLA4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui |
| Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases |
| Payment date | Validity (years) | Amount | |
| 2025-09-22 | 17 | 347.00 EUR |
| 2026-10-29 |